Smith Moore & CO. Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Smith Moore & CO. lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 26.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 45,759 shares of the biopharmaceutical company's stock after selling 16,476 shares during the period. Smith Moore & CO.'s holdings in Pfizer were worth $1,214,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. PSI Advisors LLC lifted its holdings in shares of Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after acquiring an additional 385 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. increased its holdings in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after buying an additional 391 shares during the last quarter. Lipe & Dalton increased its holdings in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC increased its stake in Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after acquiring an additional 401 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Pfizer Stock Down 5.4 %

Shares of Pfizer stock traded down $1.30 on Friday, reaching $22.99. 79,829,399 shares of the company were exchanged, compared to its average volume of 39,460,357. Pfizer Inc. has a one year low of $22.95 and a one year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average of $25.87 and a 200 day moving average of $26.76. The company has a market capitalization of $130.39 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the firm earned $0.10 earnings per share. The company's revenue was up 24.7% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.